<DOC>
	<DOC>NCT00355849</DOC>
	<brief_summary>A study to evaluate the efficacy and safety of Human Insulin Inhalation Powder [also known as AIR® Inhaled Insulin][AIR® is a registered trademark of Alkermes,Inc.] in patients with Type 2 diabetes who are currently being treated with once daily insulin glargine injections. The present study is intended to determine if mealtime AIR® Insulin may be superior to once-daily insulin glargine injections.</brief_summary>
	<brief_title>Evaluate the Efficacy and Safety of Insulin in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>type 2 diabetes mellitus one or more oral antihyperglycemic medications oncedaily insulin glargine HbA1c greater than or equal to 7.5 and less than or equal to 10.5% Nonsmoker taking a TZD dose greater than what is indicated more than two episodes of severe hypoglycemia during the 6 months prior Have had a lower respiratory infection in the 3 months prior systemic glucocorticoid therapy clinical signs or symptoms of liver disease, acute or chronic hepatitis history of renal transplantation Have an active or untreated malignancy Require more than 150 U/day of insulin glargine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>